drugset / Trial / NCT00037635

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

NCT00037635

Phase 3 Completed 400 enrolled Amgen
RandomizedParallel-groupTriple-blindTreatment

Summary

This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.

Timeline

Start
2001-12
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cinacalcet Other / unclassified 30 mg Oral
Subject Cinacalcet Other / unclassified 60 mg Oral
Subject Cinacalcet Other / unclassified 90 mg Oral
Subject Cinacalcet Other / unclassified 120 mg Oral
Subject Cinacalcet Other / unclassified 180 mg Oral